Tag: KDC-MN-055

  • CX-546

    Benzoxazine ampakine

    A second-generation Cortex Pharmaceuticals ampakine with improved AMPA receptor modulation kinetics and reduced respiratory depression liability.

    Abstract

    CX-546 (1-(1,4-benzodioxan-6-ylcarbonyl)piperidine; CAS 215923-54-9; molecular formula C14H17NO3; molecular weight 247.29) is a second-generation Cortex Pharmaceuticals ampakine in the benzoxazine subclass. The compound shows improved AMPA receptor modulation kinetics relative to CX-516, with deeper potentiation per binding event and longer-lasting effect. CX-546 was advanced through preclinical development for cognitive impairment and respiratory disorders (the AMPA potentiation can reverse opioid-induced respiratory depression in animal models). The compound did not advance through pivotal human trials in any indication. Pharmacokinetics: short plasma half-life (2 to 3 hours), oral bioavailability moderate. The compound is sold as a research chemical in jurisdictions where it is not scheduled.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.